EUVIMEDEUVIMED entdecken
Crossref

The cardiovascular effects and safety of colchicine

Gokhan Faikoglu, Fatmanur Otmar Ozcan, Kubra Saygisever-Faikoglu, Tugce Uskur, Dundar Okan Yillar, Barkin Berk, Pelin Kelicen Ugur

Pharmacy & Pharmacology International Journal · 24.03.2022 · 10 (2) · 40-45

DOI: 10.15406/ppij.2022.10.00362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy & Pharmacology International Journal, online erschienen am 24.03.2022. Verfasst von Gokhan Faikoglu und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colchicine is an alkaloid obtained from the bulb and seed of the Crocus (Colchicum autumnale L. (Liliaceae), Autumn Crocus) plant with a history of 2000 years and is currently prescribed for the treatment of rheumatic diseases. In 2015, the European Society of Cardiology supported and recommended colchicine as a first-choice treatment agent that can be added to traditional anti-inflammatory treatments to improve response to treatment, increase remission rates and reduce relapses in acute and recurrent pericarditis in the diagnosis and treatment guidelines of pericardial diseases. In addition, the use of colchicine in the Secondary Prevention of Atherosclerosis is recommended with evidence level A in the European Society of Cardiology Guidelines published in 2021. It was concluded that colchicine is a safe and effective treatment modality to prevent AF recurrence after catheter ablation. It has been noted that colchicine, used secondary to the currently used preventive drugs against CHD, has lower rates of cardiovascular death, MI, stroke, or emergency hospitalization due to angina requiring coronary revascularization, and the risk of acute cardiovascular events compared to placebo. In addition, it has been reported that the use of colchicine in patients with MI reduces the risk of ischemic cardiovascular events. Colchicine is an effective and safe option as a first-choice treatment agent that can be added to conventional anti-inflammatory treatments in patients with recurrent cardiovascular events despite optimal medical therapy and in the secondary prevention of atherosclerotic cardiovascular diseases where other risk factors cannot be adequately controlled.

Zitieren

APA

Faikoglu, G., Ozcan, F. O., Saygisever-Faikoglu, K., Uskur, T., Yillar, D. O., Berk, B., & Ugur, P. K. (2022). The cardiovascular effects and safety of colchicine. Pharmacy & Pharmacology International Journal, 10(2), 40-45. https://doi.org/10.15406/ppij.2022.10.00362

Vancouver

Faikoglu G, Ozcan FO, Saygisever-Faikoglu K, Uskur T, Yillar DO, Berk B, et al. The cardiovascular effects and safety of colchicine. Pharmacy & Pharmacology International Journal. 2022;10(2):40-45. doi:10.15406/ppij.2022.10.00362

BibTeX
@article{Faikoglu2022,
  author = {Faikoglu, Gokhan and Ozcan, Fatmanur Otmar and Saygisever-Faikoglu, Kubra and Uskur, Tugce and Yillar, Dundar Okan and Berk, Barkin and Ugur, Pelin Kelicen},
  title = {The cardiovascular effects and safety of colchicine},
  journal = {Pharmacy & Pharmacology International Journal},
  year = {2022},
  volume = {10},
  number = {2},
  pages = {40--45},
  doi = {10.15406/ppij.2022.10.00362}
}
Kostenlos starten →